Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
582.11B
Market cap582.11B
Price-Earnings ratio
21.89
Price-Earnings ratio21.89
Dividend yield
2.15%
Dividend yield2.15%
Average volume
7.37M
Average volume7.37M
High today
$245.59
High today$245.59
Low today
$241.00
Low today$241.00
Open price
$243.31
Open price$243.31
Volume
6.42M
Volume6.42M
52 Week high
$251.71
52 Week high$251.71
52 Week low
$141.50
52 Week low$141.50

Stock Snapshot

Johnson & Johnson(JNJ) stock is priced at $241.00, giving the company a market capitalization of 582.11B. It carries a P/E multiple of 21.89 and pays a dividend yield of 2.2%.

During the trading session on 2026-03-14, Johnson & Johnson(JNJ) shares reached a daily high of $245.59 and a low of $241.00. At a current price of $241.00, the stock is 0.0% higher than the low and still -1.9% under the high.

Trading volume for Johnson & Johnson(JNJ) stock has reached 6.42M, versus its average volume of 7.37M.

The stock's 52-week range extends from a low of $141.50 to a high of $251.71.

The stock's 52-week range extends from a low of $141.50 to a high of $251.71.

JNJ News

Simply Wall St 14h
Johnson And Johnson Bladder Cancer Data Adds Interest To Valuation Story

Johnson & Johnson (NYSE:JNJ) reported strong Phase 1 results for its intravesical erdafitinib drug releasing system in non muscle invasive bladder cancer. The...

Johnson And Johnson Bladder Cancer Data Adds Interest To Valuation Story
Nasdaq 15h
Johnson & Johnson Reports Promising Phase 1 Results For Erda-iDRS In Early-Stage Bladder Cancer

(RTTNews) - Johnson & Johnson (JNJ) announced new data from an open-label, multicenter Phase 1 study evaluating Erda-iDRS, an investigational intravesical drug-...

Johnson & Johnson Reports Promising Phase 1 Results For Erda-iDRS In Early-Stage Bladder Cancer
TipRanks 1d
J&J says erdafitinib met primary safety endpoint in Phase 1 study

Johnson & Johnson announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafiti...

Analyst ratings

55%

of 29 ratings
Buy
55.2%
Hold
37.9%
Sell
6.9%

More JNJ News

Simply Wall St 2d
Is Johnson & Johnson Pricing Reflect Its Strong Multi‑Year Rally And Legal Headline Risks

Wondering whether Johnson & Johnson is fairly priced at its current level, or if the market is missing something in this healthcare giant's story? The stock re...

Is Johnson & Johnson Pricing Reflect Its Strong Multi‑Year Rally And Legal Headline Risks
The Motley Fool 2d
The Best Dividend Stocks to Buy and Hold Forever

Dividend investing is a proven way to grow your wealth over the long run. But for the strategy to work, investors need to pick quality income stocks, those with...

The Best Dividend Stocks to Buy and Hold Forever
Seeking Alpha 2d
J&J wins FDA nod for Tecnis PureSee intraocular lens

Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye su...

J&J wins FDA nod for Tecnis PureSee intraocular lens
TipRanks 2d
Johnson & Johnson announces FDA approval of Tecnis PureSee IOL

Johnson & Johnson announced FDA approval of Tecnis PureSee IOL, an extended depth of focus intraocular lens intended for use in cataract surgery. Tecnis PureSee...

Simply Wall St 3d
What Johnson & Johnson's New Multiple Myeloma Combo Approval Means For Shareholders

Earlier this month, Johnson & Johnson received U.S. FDA approval for TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO for adults with relapsed or refractory mul...

What Johnson & Johnson's New Multiple Myeloma Combo Approval Means For Shareholders
Nasdaq 3d
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever

Success in business is challenging. Most new ventures don't last more than a decade. A few select companies survive and thrive for several decades. Fewer still...

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
TipRanks 3d
Johnson & Johnson price target raised to $274 from $250 at Citi

Citi raised the firm’s price target on Johnson & Johnson to $274 from $250 and keeps a Buy rating on the shares. The firm adjusted targets in the medical techno...

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.